Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib in adolescents with chronic spontaneous urticaria inadequately controlled by H1-antihistamines
jRCT2031230679Active, not recruiting
- Sponsor
- Novartis
- Start
- Apr 2024
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in chronic idiopathic urticaria (CIU) comparing Remibrutinib arm with Placebo arm (2 arms). Primary endpoints: Change from baseline in UAS7 at Week 12, Change from baseline in ISS7 at Week 12 and 1 more. Started Apr 2024; status: active, not recruiting.
02
Drugs
remibrutinib
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on jRCT2031230679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230679.